Skip to main content
Open Access Publications from the University of California


UCLA Previously Published Works bannerUCLA

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.

Published Web Location
No data is associated with this publication.

Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item